ADMA Earnings Date: Nov 4, 2026 (Estimated) — ADMA Biologics, Inc.
NASDAQ · Healthcare · Biotechnology
Updated
When is ADMA's next earnings date?
ADMA Biologics, Inc. (ADMA) is expected to report Q3 2026 earnings on Wednesday, November 4, 2026 at 4:00 PM ET (after market close); the date is an estimate and has not been confirmed by the company. The consensus estimate is EPS of $0.20 on revenue of $138.1M.
How did ADMA do in its last earnings report?
In its most recent report on Aug 5, 2026 (Q2 2026), ADMA Biologics, Inc. posted EPS of $0.16 versus the $0.16 estimate, a miss of 5.9%. Revenue was $124.4M against a $125.3M estimate. The stock's 1-day post-earnings move was +8.6%.
How much does ADMA stock move after earnings?
ADMA beat EPS estimates in 3 of its last 8 reported quarters. Over the last 8 reports the stock moved an average of 8.6% (up or down) in the day after earnings.
About ADMA Biologics, Inc.
ADMA Biologics, Inc. functions as a biopharmaceutical company specializing in the development, manufacturing, and commercialization of advanced biologic therapies derived from blood plasma. These specialized products are engineered to address immune system disorders and infectious diseases, catering to markets across the United States and internationally. Their current product portfolio includes BIVIGAM and ASCENIV, both intravenous immune globulin (IVIG) treatments prescribed for primary humoral immunodeficiency (PI). Additionally, the company offers Nabi-HB, utilized for immediate treatment following acute exposure to the Hepatitis B virus and other specified exposures. Beyond its existing offerings, ADMA is actively developing a pipeline of new plasma-derived therapeutics. This includes immunoglobulin products specifically targeting the prevention and treatment of S. pneumonia infections. The company also oversees its own facilities for source plasma collection. Product distribution is managed through a comprehensive network involving independent distributors, sales agents, specialty pharmacies, and other alternative healthcare providers. ADMA Biologics, Inc. was founded in 2004 and maintains its corporate headquarters in Ramsey, New Jersey.
Earnings History
| Date | Period | EPS Est. | EPS Act. | Surprise | Revenue | Result | 1D Δ | 1W Δ | 1M Δ |
|---|---|---|---|---|---|---|---|---|---|
| 2026-08-05 | Q2 2026 | 0.16 | 0.16 | -5.88% | $124.4M | ❌ Miss | +8.64% | +5.62% | +3.46% |
| 2026-05-06 | Q1 2026 | 0.20 | 0.17 | -15.00% | $114.5M | ❌ Miss | -15.97% | -15.67% | -20.93% |
| 2026-02-25 | Q4 2025 | 0.20 | 0.21 | +7.50% | $139.2M | ✅ Beat | -3.19% | +5.48% | -47.13% |
| 2025-11-05 | Q3 2025 | 0.16 | 0.16 | +0.00% | $134.2M | ➖ Inline | -8.72% | +7.09% | +29.15% |
| 2025-08-06 | Q2 2025 | 0.14 | 0.14 | +0.00% | $122.0M | ➖ Inline | -9.65% | -7.23% | -9.01% |
| 2025-03-03 | Q4 2024 | 0.15 | 0.14 | -6.67% | $117.5M | ❌ Miss | +7.45% | +4.93% | +22.68% |
| 2024-11-07 | Q3 2024 | 0.13 | 0.15 | +15.38% | $119.8M | ✅ Beat | +14.71% | +2.43% | -3.60% |
| 2024-02-28 | Q4 2023 | 0.02 | 0.04 | +100.00% | $73.9M | ✅ Beat | -0.37% | +13.75% | +22.68% |
Showing last 8 quarters.
Revenue by segment & region
By segment
Q4 FY24 · $117.2M total
| Segment | Share | Revenue | YoY | Q2 FY23 | Q3 FY23 | Q4 FY23 | Q1 FY24 |
|---|---|---|---|---|---|---|---|
| ADMA BioManufacturing | 99.3% | $116.4M | +124.7% | $59.8M | $66.6M | $51.8M | $80.1M |
| Plasma Collection Centers | 0.7% | $804K | +64.5% | $326K | $888K | $489K | $1.8M |
By region
Q2 FY26 · $124.4M total
| Segment | Share | Revenue | YoY | Q4 FY24 | Q1 FY25 | Q2 FY25 | Q3 FY25 |
|---|---|---|---|---|---|---|---|
| UNITED STATES | 99.1% | $123.3M | +1.1% | — | $110.7M | $122.0M | $134.0M |
| Non-US | 0.9% | $1.1M | — | — | $4.1M | — | $246K |
Source: company filings via FMP. YoY compares the same fiscal period a year earlier.